Article | September 23, 2026
When does my study require GCLP? A guide for selecting the right regulatory framework
Regulatory nomenclature in the pharma industry can be confusing, particularly when it comes to GxP guidance. GxP is an umbrella term encompassing many sets of “Good Practice” quality standards and regulations that span the pharma R&D pipeline, aimed at ensuring the integrity and safety of therapeutics and medical devices that have direct impact on patients’ health. Collectively, GxP regulations establish standardized quality frameworks for developing, testing, and distributing these products – protecting patients from unacceptable risk and companies from costly regulatory actions.
The “x” is a placeholder that references a specific discipline or area of operation within the development lifecycle, each with its own specific practices: from Good Laboratory Practice (GLP) to Good Clinical Laboratory Practice (GCLP), Good Clinical Practice (GCP), and Good Manufacturing Practice (GMP), among other GxP frameworks.
There is no single entity that oversees all GxP regulations, and agency expectations are as varied as the environments each GxP applies to. The challenge is that all GxP standards do share similar foundational goals related to data integrity, documentation, and traceability, creating a common misconception that the frameworks are interchangeable. The varied acronyms also create an “alphabet soup” problem that muddles clarity on exactly what each framework addresses. This may lead to overfitting or underfitting compliance at a given study phase, which can waste precious time, add unnecessary expense, and in some cases, open the study to regulatory penalties.
In this blog, we take a closer look at GLP, GCLP, and GCP specifically – principles that are often grouped together but that are actually quite distinctive – to define where they apply in the drug development process and to provide a decision framework for selecting the right compliance level for your program.
From the Lab to the Clinic: Where GLP, GCP, and GCLP Fit
GLP, GCP, and GCLP address quality practices related to the research and testing of drug candidates at different points of the development pipeline.
Good Laboratory Practice (GLP): for non-clinical safety studies
GLP applies to preclinical safety studies conducted in animals or other non-human models. It lays out quality system requirements for toxicology, pharmacokinetic (PK), and toxicokinetic (TK) studies aimed at demonstrating safety and desired pharmacological activity for drug candidates intended for human testing.
Codified in the United States by the FDA’s CFR Title 21 CFR Part 58 and mirrored internationally by the OECD Principles of Good Laboratory Practice, GLP regulations and guidance have a focused scope: ensure safety data generated for a new compound is complete, traceable, and reliable enough for regulators to make confident decisions about approving its experimental use in humans.
GLP principles must be followed for safety studies supporting IND submissions. It is important to note that the guidance is also explicit as to where GLP is not applicable: it excludes all human clinical studies, basic non-clinical research and discovery toxicology studies, and non-clinical PK evaluations that are not part of a GLP study.
Good Clinical Practice (GCP): for clinical trial execution
GCP, on the other hand, is the ethical and scientific quality standard for clinical trials that involve human subjects. It governs how a trial is designed, conducted, recorded, and reported to ensure the safety, well-being, and rights of study participants are upheld and that reported trial data is credible. GCP regulations cover everything from informed consent to investigator responsibilities, adverse event reporting, and auditing and inspections.
The ICH E6 guideline – also known as the Good Clinical Practice guideline – provides a unified framework that is accepted by regulatory authorities in the United States, EU, and Japan, though each country has variability in how they enforce the regulations locally.
The scope of GCP is focused on trial execution and trial data reporting integrity, not on whether the specific datasets reported were generated correctly.
Good Clinical Laboratory Practice (GCLP): for lab analysis of clinical trial samples
GCLP is a quality system that bridges the laboratory rigor of GLP and the clinical trial oversight of GCP. This framework ensures that laboratory work supporting clinical trials is conducted, documented, monitored, and reported in a manner that produces reliable, accurate, and auditable results. Its scope is focused on laboratory practices that support human-derived sample analysis and that report results for the diagnosis and/or treatment of clinical trial participants.
GCLP compliance demands rigorous controls for instrument qualification, assay precision and accuracy, and documentation and traceability via a validated LIMS system to produce quality assay data in a manner that also protects the safety, rights, and confidentiality of participants.
While there is no single global regulatory mandate for GCLP, international frameworks like the World Health Organization’s Good Clinical Laboratory Practice guidance provide the best practices framework for labs to adhere to. In the United States, GCLP compliance is based on a lab’s own internal assessment and is the sponsor’s responsibility to audit, whereas in the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) folds GCLP into its broader GCP inspection remit.
GCLP: A quality framework that fills a critical gap
GCLP is a newer GxP standard created specifically because neither GLP nor GCP fully addresses a vital aspect of clinical development: the laboratory testing of samples collected from clinical trials. GLP is not designed for studies handling human specimens, and GCP was not written to cover the operational aspects of clinical laboratory testing.
Learn more about GCLP-compliant workflows
GCLP takes many of GLP’s stringent standards for equipment qualification, method validation, and data integrity and applies them within a GCP-compliant clinical trial context to uphold ethical standards relating to participant rights and privacy. The goal of GCLP is to ensure the measures reported by a lab supporting active clinical trials – including for primary and secondary endpoints – are accurate, reliable, fully traceable, and in compliance with ethical consent, equipping clinical trial sponsors with decision-grade data to act upon.
Choosing the right GxP for your study: a decision framework
It is important to match the right GxP framework to the specific needs of your study at the phase you are in. The wrong selection can lead to either over-building compliance that is not actually needed – creating unnecessary layers of complexity and expense – or under-building quality systems with compliance gaps that ultimately require work to be re-run.
The following table can provide a helpful starting point to determine which framework, if any, is best for your study goals and how the data will be used:
| Category | Scope | Compliance Level |
|---|---|---|
| Preclinical – Exploratory | Discovery, screening, and/or hypothesis generation in non-clinical models (not tied to a protocol endpoint or regulatory submission) | GLP not required |
| Preclinical – Safety Data for Regulatory Submission | Any data from a non-clinical safety or toxicology study used to support an Investigational New Drug (IND) application, New Drug Application (NDA), or Biologics License Application (BLA) | GLP required |
| Clinical – Exploratory | Discovery, screening, and/or hypothesis generation in human samples (not tied to a protocol endpoint, patient enrollment / stratification, or regulatory submission*) *Exploratory biomarker data included in an IND, NDA, or BLA package is subject to GCLP | GCLP not required* |
| Clinical – Clinical Trial Testing | Data generated in human-derived clinical trial samples used to:
| GCLP required |
| Clinical – Clinical Trial Execution | Protocol execution, informed consent, investigator oversight, monitoring, and adverse event reporting for the trial itself | GCP required |
It is important to note that GCP runs in parallel with GCLP – not replacing it – when a trial with human participants has lab-tested samples.
Finding the right-fit partner: as important as the right quality framework
As you can see, there are many nuances in the quality standards and regulations that pharma R&D teams must navigate as they move their compounds through development. That is why it is critical to find a laboratory partner with the expertise to help you right-fit your compliance framework to the true scope of how your data will be used.
As a lab supporting sample analysis at all phases of the drug development pipeline, Sapient has GCLP-compliant workflows, which adhere to WHO’s GCLP guidance, that we use for clients requiring assays for active clinical trials – including for primary and secondary endpoints.
These workflows leverage our validated instrumentation, quality management system (QMS), and laboratory information system (LIMS) as part of a documented quality framework that aligns with global regulatory authorities’ expectations for clinical trial biomarker testing. The framework is supported by our team’s deep QA and regulatory expertise, comprising quality and scientific leaders with decades of combined experience implementing GxP standards.
If you are scoping a study and need guidance to align the proper regulatory framework, or are actively pursuing human clinical trials and need compliant support for laboratory testing, Sapient’s team can help. We also welcome sponsor audits to review our GCLP processes and procedures. Reach out the set up a time to talk here.